Upcoming conferences
Some of our team members will be attending the New Horizons in Neurodegeneration conference on October 9-10, 2025 in Leuven : Pierre Vandepapelière – CEO Damien Toulorge – CSO Julie Goemaere – R&D Director Aditya Iyer – R&D Senior Project Manager Elodie Hendrick – R&D Laboratory Manager Dafni Birmpili – R&D Project Associate Our CSO, […]
BIO International Convention – Boston 2025
What a nice experience for our CSO to represent Amyl in Boston at the world’s largest biotech gathering ! More than 20,000 professionals from accross the globe attended. Damien Toulorge shared our technology and recent advances. This was a great recognition for our scientific team and a unique opportunity to highlight our commitment to neurodegenerative diseases.
Team Building Event 2025
What a day! We kicked off the morning paddling through the water on a kayak expedition, testing our balance, coordination, and—let’s be honest—our ability to laugh through unexpected tumbles! 🌊😆 The afternoon brought a collaboration course, where teamwork, strategy, and communication were key. Lots of laughs, a few splashes, and plenty of lessons in trust […]
LSX Nordic Congress 2025
On May 20th and 21st, our CEO, Pierre Vandepapelière, was in Bergen for the LSX Nordic Congress. He had the opportunity to present our breakthrough therapy : a single product to clear the brain from all types of amyloids.
Swiss Biotech Day 2025 – Amyl, one of the nine startups selected to pitch
On May 5th, our CEO, Pierre Vandepapelière, had the opportunity of presenting our technology to an engaged audience at the Congress Center Basel during the Swiss Biotech Day. This year, over 25 startups from all delegations applied, only 9 were selected, and Amyl was part of them. Thank you to the Swiss Biotech Day team for […]
LSX World Congress 2025
We never stop at Amyl Therapeutics !🚀 On April 29th, our CEO, Pierre Vandepapelière, attended the LSX World Congress conference that took place at the Business Design Center in London. During this leading event dedicated to innovation and investment in the life sciences and healthcare sector, he had the opportunity to present our Pan-Amyloid Immunotherapy technology, […]
Amyl Therapeutics – One of the ten startups selected to pitch at BioVaria
We are proud to announce that Amyl Therapeutics was the one of the 10 startups selected to pitch at the BioVaria conference in Munich on April 28, 2025. Our presentation was focus on our innovative technology, which we believe has the potential to transform the neurodegenerative research sector. Thank you to the BioVaria team for […]
2025 AD/PD conference
Damien Toulorge, Julie Goemaere and Aditya Iyer attended the Alzheimer’s & Parkinson’s Diseases Conference in Vienna, Austria, from April 1-5, 2025. Aditya Iyer, our Senior Project Manager, presented a poster describing Amyl technology and results. The team came back even more convinced that Amyl strategy is the best to find a universal treatment for neurodegenerative […]
Laborama 2025 in Brussels
Last week, our laboratory team had the pleasure of attending Laborama 2025 at Brussels Expo. They explored cutting-edge innovations and connected with passionate professionals in the field. Beyond the insights and networking, this event was also a wonderful occasion for the lab team to spend quality time together, strengthening their collaboration and shared vision.
Fire training
Last week, our R&D Director, Julie Goemaere, and our Senior Project Manager, Aditya Iyer, attended a fire training. The fire triangle and all the other basics in the event of a fire no longer hold any secrets for them ! Amyl puts safety and well-being at work at the heart of its preoccupations. Reacting quickly […]